OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
N6-methyladenosine (m6A) in cancer therapeutic resistance: Potential mechanisms and clinical implications
Dong Wang, Yan Zhang, Qingbo Li, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 167, pp. 115477-115477
Open Access | Times Cited: 8
Dong Wang, Yan Zhang, Qingbo Li, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 167, pp. 115477-115477
Open Access | Times Cited: 8
Showing 8 citing articles:
Pharmacology of Epitranscriptomic Modifications: Decoding the Therapeutic Potential of RNA Modifications in Drug Resistance
Abdullah Alkhammash
European Journal of Pharmacology (2025) Vol. 994, pp. 177397-177397
Closed Access
Abdullah Alkhammash
European Journal of Pharmacology (2025) Vol. 994, pp. 177397-177397
Closed Access
Molecular mechanism of ZC3H13 -mediated ferroptosis in doxorubicin resistance of triple negative breast cancer
Li‐Shan Huang, Lei Han, Shuai Liang, et al.
Cell Biology and Toxicology (2025) Vol. 41, Iss. 1
Open Access
Li‐Shan Huang, Lei Han, Shuai Liang, et al.
Cell Biology and Toxicology (2025) Vol. 41, Iss. 1
Open Access
Min Fu, Qian Gao, Mian Xiao, et al.
Oral Diseases (2024) Vol. 30, Iss. 7, pp. 4341-4355
Closed Access | Times Cited: 1
METTL3 inhibitor suppresses the progression of prostate cancer via IGFBP3/AKT pathway and synergizes with PARP inhibitor
Xin Chen, Miaomiao Wang, Haoran Wang, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 179, pp. 117366-117366
Open Access | Times Cited: 1
Xin Chen, Miaomiao Wang, Haoran Wang, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 179, pp. 117366-117366
Open Access | Times Cited: 1
Landscape of m6A RNA methylation regulators in liver cancer and its therapeutic implications
Jindu Zhao, Guoying Li, Xianying Lu, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access
Jindu Zhao, Guoying Li, Xianying Lu, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access
Multifaceted bioinformatic analysis of m6A ‐related ferroptosis and its link with gene signatures and tumour‐infiltrating immune cells in gliomas
Yang Yang, Hao Liu, Guiyang Liu, et al.
Journal of Cellular and Molecular Medicine (2024) Vol. 28, Iss. 17
Open Access
Yang Yang, Hao Liu, Guiyang Liu, et al.
Journal of Cellular and Molecular Medicine (2024) Vol. 28, Iss. 17
Open Access
M6A and lactylation modification-related signature predicts prognosis and immunotherapy response in hepatocellular carcinoma
Ren Hui-li, Jianhua Liu, Shaohui Zhang
(2024)
Closed Access
Ren Hui-li, Jianhua Liu, Shaohui Zhang
(2024)
Closed Access
METTL3-mediated m6A modification promotes chemoresistance of intrahepatic cholangiocarcinoma by up-regulating NRF2 to inhibit ferroptosis in cisplatin-resistant cells
Xiaoping Zheng, Huiying Li, Jian Lin, et al.
Journal of Chemotherapy (2024), pp. 1-11
Closed Access
Xiaoping Zheng, Huiying Li, Jian Lin, et al.
Journal of Chemotherapy (2024), pp. 1-11
Closed Access
